NanosiRNA® COVID-19: specific antiviral treatment Medesis Pharma has a microemulsion
Medesis Pharma is developing a radioprotection drug to treat people irradiated following
Text currently
Alzheimer’s disease is the most frequent cause of dementia and one of the most
The objective of the radioprotection program is to develop a radiomitigation drug,
NU02 Cesium decorporation 137Cs is gamma and beta emitting by-product of uranium
AONYS® is a mix of lipidic components that spontaneously assemble into a water-in-oil
NanoLithium® (NP03) is a disease-modifying nano dose formulation of lithium citrate
NU01 Plutonium decorporation Plutonium (Pu) is an alpha emitting radionuclide which
Huntington’s Disease (HD) is a fatal autosomal dominant progressive neurodegenerative
